Skip to content

Clinical trials

Phase 1/2 Autoimmune Diseases trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Autoimmune Diseases Phase: Phase 1/2 Clear all

53 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20032
20061
20071
20082
20102
20111
20124
20132
20142
20151
20161
20172
20191
20202
20211
20223
20232
20248
20255
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting13
Completed13
Terminated8
Not yet recruiting7
Withdrawn4
Unknown status3
Active, not recruiting3
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Cabaletta Bio4
Essen Biotech3
Kyverna Therapeutics3
University of Sao Paulo3
National Heart, Lung, and Blood Institute (NHLBI)2
National Institute of Allergy and Infectious Diseases (NIAID)2
Shenzhen Geno-Immune Medical Institute2
University of Jordan2
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud1
Assistance Publique - Hôpitaux de Paris1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Autoimmune Diseases53
Lupus Erythematosus, Systemic12
Multiple Sclerosis9
Immune System Diseases8
Lupus Nephritis7
Arthritis, Rheumatoid6
Diabetes Mellitus, Type 16
Diabetes Mellitus5
Scleroderma, Systemic5
Nervous System Diseases4

Trials

Showing 26 to 50 of 53. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.